Insmed Incorporated (INSM), a biopharmaceutical company, is showing positive developments in its product portfolio. The company reiterated its 2023 guidance, expecting revenue between $295-305 million, with strategic plans to expand the use of its ARIKAYCE product.
Encouraging Phase 2 data for its TPIP drug, used in pulmonary hypertension treatment, highlights...
NASDAQ:INSM
Possible Scenario: LONG
Evidence: Price Action, Money Flow
Period: Less than two months.
TP1: 28.5$
TP2: 29.5$
TP3: 31$
*This is my idea and could be wrong 100%.
Hey guys, INSMED is in a bullish push with high volume buy executed and a water-carrying candle shape followed by short legs. The TIMEFRAME M1 shows us a kind of hammer candle with a high negotiated sales volume, it wanted to bounce back from the bollinger base. But it was a failure passing on its low point to come back to test the base and the top of the...
1. Not up three days in a row
2. Linear move up prior to consolidation
3. Young Trend
4. No breakouts or breakdowns during consolidation phase
5. Clean and low volatility consolidation
***see roboticinvesting.com for more details on Momentum Surge
Did we miss the short since it kept topping out??
We did have a target on the short to close the gap.
The long may not have been so obvious, with an exit at the 2nd arrow and red horizontal....
